TR200401267T4 - Aşı maddesi olarak antikorların yeni kullanımları. - Google Patents

Aşı maddesi olarak antikorların yeni kullanımları.

Info

Publication number
TR200401267T4
TR200401267T4 TR2004/01267T TR200401267T TR200401267T4 TR 200401267 T4 TR200401267 T4 TR 200401267T4 TR 2004/01267 T TR2004/01267 T TR 2004/01267T TR 200401267 T TR200401267 T TR 200401267T TR 200401267 T4 TR200401267 T4 TR 200401267T4
Authority
TR
Turkey
Prior art keywords
antibodies
cleansing
vaccines
associated antigens
immune affinity
Prior art date
Application number
TR2004/01267T
Other languages
English (en)
Inventor
Loibner Hans
Eckert Helmut
Himmler Gottfried
Original Assignee
Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag filed Critical Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag
Publication of TR200401267T4 publication Critical patent/TR200401267T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Timörle birlesmis antijenlere karsi antikorlara baglanan ve kisiye özel vücut sivilarindan ve özel baglarda immün afinite temizligi yolu ile elde edilen antikorlarin, kansere karsi, kisiye özel, otolog profilaktik ya da terapötik asilama için bir bilesimin imal edilmesine yönelik kullanimi tanimlanmaktadir. Immün afinite temizliginin baglari, tümörle birlesmis antijenlere karsi hareket eden antikorlar ya da onlarin türevleridir. Ayrica bulus immün afinite temizligi yolu ile elde edilmis antikorlari veya bunlar ile birlikte in vitro olarak salinimli dendritik hücreler içeren farmasötik bilesimler ile de ilgilidir.
TR2004/01267T 1999-11-16 2000-11-15 Aşı maddesi olarak antikorların yeni kullanımları. TR200401267T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0192799A AT409086B (de) 1999-11-16 1999-11-16 Neue verwendung von antikörpern als impfstoffe

Publications (1)

Publication Number Publication Date
TR200401267T4 true TR200401267T4 (tr) 2004-07-21

Family

ID=3524036

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2004/01267T TR200401267T4 (tr) 1999-11-16 2000-11-15 Aşı maddesi olarak antikorların yeni kullanımları.

Country Status (24)

Country Link
EP (1) EP1229936B1 (tr)
JP (1) JP2003514028A (tr)
KR (1) KR20020060968A (tr)
CN (1) CN1390138A (tr)
AT (1) AT409086B (tr)
AU (1) AU780853B2 (tr)
BR (1) BR0015597A (tr)
CA (1) CA2391927A1 (tr)
CZ (1) CZ20021707A3 (tr)
DE (1) DE50006526D1 (tr)
DK (1) DK1229936T3 (tr)
EE (1) EE200200252A (tr)
ES (1) ES2218272T3 (tr)
HU (1) HUP0204216A2 (tr)
IL (1) IL149614A0 (tr)
IS (1) IS6381A (tr)
MX (1) MXPA02004942A (tr)
NO (1) NO20022333L (tr)
NZ (1) NZ518669A (tr)
PL (1) PL356770A1 (tr)
PT (1) PT1229936E (tr)
SK (1) SK6542002A3 (tr)
TR (1) TR200401267T4 (tr)
WO (1) WO2001035989A2 (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017108A (en) * 1975-04-17 1977-04-12 Archibald Kenrick And Sons Limited Window stay
US6294171B2 (en) * 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
AT410172B (de) * 2000-03-21 2003-02-25 Igeneon Gmbh Verfahren zur herstellung einer vakzineformulierung
AT410637B (de) * 2001-06-01 2003-06-25 Igeneon Krebs Immuntherapie Verwendung von polyklonalen immunglobulinen
AT502293B1 (de) * 2002-05-15 2008-03-15 Igeneon Krebs Immuntherapie Immunogener, monoklonaler antikörper
AT500648B1 (de) 2002-08-12 2010-03-15 Igeneon Krebs Immuntherapie Set zur behandlung von krebspatienten
KR100522526B1 (ko) * 2002-11-28 2005-10-19 주식회사 바이넥스 면역 치료용 수지상 세포의 제조방법
AT500650B1 (de) * 2003-04-17 2009-11-15 Altropus Gmbh Immunogener rekombinanter antikörper
US20070048795A1 (en) * 2005-08-26 2007-03-01 Xiangming Fang Immunoaffinity separation and analysis compositions and methods
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
US20180008702A1 (en) * 2014-12-05 2018-01-11 Celltrion Inc. Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002848A1 (en) * 1983-01-28 1984-08-02 Centocor Inc Anti-idiotypic antibodies to t cell antigen receptors
JPH03501209A (ja) * 1988-05-17 1991-03-22 フェロン、ソルダノ 抗ヒト高分子量メラノーマ関連抗原に対する抗イディオタイプ抗体
US20030072751A1 (en) * 1990-03-14 2003-04-17 Heribert Bohlen Idiotypic vaccination against b cell lymphoma
IT1254315B (it) * 1992-03-27 1995-09-14 Mini Ricerca Scient Tecnolog Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf.
TNSN93075A1 (fr) * 1992-07-08 1994-03-17 Schering Corp Utilisation de gm-csf comme adjuvant pour vaccin
AU717779C (en) * 1994-12-28 2002-12-05 University Of Kentucky Recombinant anti-idiotype antibody 3H1 sequences relating to human carcinoembryonic antigen

Also Published As

Publication number Publication date
DK1229936T3 (da) 2004-08-30
IL149614A0 (en) 2002-11-10
PT1229936E (pt) 2004-09-30
NO20022333L (no) 2002-06-03
AU2357201A (en) 2001-05-30
DE50006526D1 (de) 2004-06-24
NO20022333D0 (no) 2002-05-15
WO2001035989A2 (de) 2001-05-25
NZ518669A (en) 2003-08-29
CZ20021707A3 (cs) 2002-10-16
EP1229936A2 (de) 2002-08-14
ES2218272T3 (es) 2004-11-16
CA2391927A1 (en) 2001-05-25
BR0015597A (pt) 2002-07-23
IS6381A (is) 2002-05-14
ATA192799A (de) 2001-10-15
HUP0204216A2 (en) 2003-04-28
EP1229936B1 (de) 2004-05-19
AU780853B2 (en) 2005-04-21
CN1390138A (zh) 2003-01-08
WO2001035989A3 (de) 2001-10-04
MXPA02004942A (es) 2003-10-14
JP2003514028A (ja) 2003-04-15
PL356770A1 (en) 2004-07-12
AT409086B (de) 2002-05-27
SK6542002A3 (en) 2002-11-06
EE200200252A (et) 2003-06-16
KR20020060968A (ko) 2002-07-19

Similar Documents

Publication Publication Date Title
PH12023550266A1 (en) Anti-ceacam5 antibodies and conjugates and uses thereof
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
EP2562183A8 (en) Novel immunogenic epitopes for immunotherapy
MXPA02005639A (es) Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
BG109311A (en) PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNFAL, AND HIS APPLICATION
TR200103018T2 (tr) İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
FI1897548T4 (fi) T-solujen säätely
UA109633C2 (uk) Антитіло людини проти тканинного фактора
WO2006037421A3 (en) Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes
MXPA04004417A (es) Anticuerpo anti-tnf alfa modificado.
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
EA200301159A1 (ru) Цитотоксические иммуноконъюгаты антитела к cd44
JP2008508189A5 (tr)
TR200102493T2 (tr) IgE'nin C-epsilon-3 veya C-epsilon-4 alanlarından türetilmiş epitoplar veya mimotoplar.
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
BR0015597A (pt) Uso de anticorpos como vacinas
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
TR200001948T2 (tr) Mikobakteri vaccaesinden türetilen kompozisyonlar ve bunların kullanımları için metotlar.
ATE283354T1 (de) Peptid aus antigen muc-1 zur auslösung einer immunreaktion gegen tumorzellen
DE69530380D1 (de) Retropeptide, antikörper dagegen und deren verwendungen in der impfung und in vitro diagnostik
DE69921486D1 (de) Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren
WO2002047613A3 (en) Immunogenic cancer peptides and uses thereof
JP2005524719A5 (tr)
DE60109922D1 (de) Therapeutische verbindungen gegen eierstockkrebs
DE60040672D1 (de) Antikörper-abhängige vergrösserung der alphavirus-infektvität